Drug intelligence / Profile preview

olanzapine + vitamin d + vitamin e

Development stage: Preclinical
Lead developer: Teva Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy approach using olanzapine (an atypical antipsychotic), vitamin D, and vitamin E. This combination has been studied for its potential to reduce the adverse effects associated with olanzapine treatment, particularly dyslipidemia, while potentially improving psychiatric outcomes in patients with mental health disorders.

Targets

DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on olanzapine + vitamin d + vitamin e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olanzapine + vitamin d + vitamin e.

Explore the full profile